Latest Ratios: P/E Ratio 4.0x · EV/EBITDA 14.0x · ROE 27.0%. (2011–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $311M | $431M | $346M | $264M | $746M | $758M | $385M | $262M | $43M | $7M | $13M |
| Enterprise Value | $302M | $422M | $289M | $241M | $709M | $736M | $378M | $259M | $45M | $9M | $12M |
| P/E Ratio → | 3.96 | 10.53 | 16.84 | 18.44 | 43.23 | 54.02 | 25.53 | 52.12 | — | — | — |
| P/S Ratio | 5.52 | 7.65 | 5.08 | 4.66 | 14.07 | 19.64 | 11.76 | 12.21 | 3.47 | 1.00 | 1.80 |
| P/B Ratio | 0.70 | 1.87 | 4.82 | 4.74 | 16.38 | 25.45 | 29.48 | 62.55 | — | — | — |
| P/FCF | — | — | 20.38 | 17.25 | 48.97 | 52.82 | 34.94 | 68.12 | — | — | — |
| P/OCF | 12.73 | 17.65 | 19.43 | 15.12 | 46.46 | 50.17 | 30.28 | 55.88 | 69.63 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.50 | 4.24 | 4.26 | 13.37 | 19.07 | 11.53 | 12.06 | 3.59 | 1.27 | 1.74 |
| EV / EBITDA | 14.04 | 19.63 | 12.66 | 13.56 | 35.33 | 44.51 | 33.31 | 44.34 | — | — | — |
| EV / EBIT | 14.43 | 20.17 | 12.58 | 14.02 | 36.44 | 44.65 | 35.27 | 48.52 | — | — | — |
| EV / FCF | — | — | 17.02 | 15.76 | 46.54 | 51.28 | 34.24 | 67.26 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.5% | 91.5% | 89.8% | 92.5% | 88.5% | 91.3% | 88.8% | 87.4% | 79.5% | 74.8% | 59.3% |
| Operating Margin | 37.2% | 37.2% | 32.6% | 30.3% | 36.7% | 41.3% | 32.7% | 24.9% | -6.9% | -29.0% | -120.3% |
| Net Profit Margin | 72.7% | 72.7% | 30.2% | 25.3% | 32.5% | 36.3% | 46.0% | 23.3% | -12.1% | -34.4% | -121.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 27.0% | 27.0% | 32.3% | 28.3% | 45.7% | 65.4% | 174.7% | 621.7% | — | — | -719.2% |
| ROA | 25.7% | 25.7% | 29.2% | 25.3% | 40.4% | 52.9% | 116.0% | 83.9% | -41.3% | -83.0% | -160.7% |
| ROIC | 13.3% | 13.3% | 70.0% | 62.2% | 179.3% | 183.5% | 257.2% | 439.3% | — | — | — |
| ROCE | 13.7% | 13.7% | 34.9% | 33.9% | 51.2% | 73.9% | 123.9% | 323.3% | — | — | -699.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.79 | -0.41 | -0.81 | -0.74 | -0.59 | -0.78 | — | — | — |
| Net Debt / EBITDA | -0.41 | -0.41 | -2.50 | -1.28 | -1.84 | -1.34 | -0.68 | -0.56 | — | — | — |
| Debt / FCF | — | — | -3.36 | -1.49 | -2.43 | -1.54 | -0.70 | -0.85 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | 17.93 | -1.84 | -5.52 | -97.90 |
Net cash position: cash ($9M) exceeds total debt ($70000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.59 | 3.59 | 10.64 | 7.13 | 9.33 | 5.89 | 2.20 | 1.78 | 0.56 | 0.49 | 0.43 |
| Quick Ratio | 3.54 | 3.54 | 10.56 | 7.06 | 9.22 | 5.82 | 2.20 | 2.57 | 0.82 | 0.76 | 0.74 |
| Cash Ratio | 2.36 | 2.36 | 9.23 | 6.28 | 7.65 | 4.89 | 1.49 | 0.94 | 0.28 | 0.19 | 0.10 |
| Asset Turnover | — | 0.23 | 0.87 | 0.90 | 1.05 | 1.11 | 1.79 | 2.78 | 2.94 | 2.42 | 2.27 |
| Inventory Turnover | 13.29 | 13.29 | 15.69 | 9.07 | 11.13 | 9.87 | — | — | — | — | — |
| Days Sales Outstanding | — | 28.39 | 32.79 | 25.01 | 24.91 | 26.55 | 38.83 | 47.57 | 38.55 | 43.06 | 66.63 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 25.2% | 9.5% | 5.9% | 5.4% | 2.3% | 1.9% | 3.9% | 1.9% | — | — | — |
| FCF Yield | — | — | 4.9% | 5.8% | 2.0% | 1.9% | 2.9% | 1.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.6% | 1.9% | 0.0% | 0.0% | 1.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.6% | 1.9% | 0.0% | 0.0% | 1.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $5M | $5M | $5M |
Treasury asset volatility
As reported in recent financial filings, SMLR's P/E ratio of 3.96 appears deceptively low, reflecting significant non-operating gains from digital asset holdings rather than core medical device earnings, which warrants caution for investors attempting to apply traditional healthcare valuation multiples to this hybrid financial-industrial entity.
The current valuation metrics are heavily skewed by the company's recent shift toward a Bitcoin-centric treasury strategy, rendering standard P/E and EV/EBITDA multiples unreliable for assessing operational performance. Investors should monitor the divergence between the core medical device business's declining revenue and the volatility of the company's non-operating asset portfolio.
Based on reported figures, SMLR's operating margin has deteriorated to -72.0% in 2025Q3, highlighting a sharp contrast with the 2.3% net margin, which suggests that the company's bottom-line profitability is now primarily driven by non-recurring financial items rather than the underlying QuantaFlo diagnostic service.
The persistent erosion of operating margins indicates that the company's fixed cost base is no longer scaling effectively against its contracting revenue. This decoupling of operating and net margins suggests that the firm's true earning power from its medical device operations is currently obscured by significant non-operating volatility.
According to recent quarterly data, SMLR's ROIC has trended into negative territory, reaching -0.8% in 2025Q3, a significant decline from the 34.8% peak observed in 2024Q1, which indicates that the company is struggling to generate meaningful returns on its increasingly large and intangible-heavy asset base.
The rapid decay in return on invested capital reflects both the contraction in core diagnostic revenue and the inefficient allocation of capital toward non-operating assets. This trend suggests that the company's historical ability to compound capital through high-margin medical services is currently being undermined by its recent strategic pivot.
As indicated by recent SEC filings, the cash conversion cycle has ballooned to 2039 days in 2025Q3, a dramatic increase from historical norms, which suggests that the company is facing significant challenges in managing its receivables and inventory turnover within the current Medicare Advantage reimbursement environment.
The extreme lengthening of the cash conversion cycle points to potential friction in collecting payments from major healthcare payers, which may be tightening their own screening protocols. This inefficiency in working capital management further complicates the company's liquidity position and ability to fund operations through internal cash generation.
Based on reported figures, the P/E ratio is the most commonly misapplied metric for SMLR, as it fails to account for the massive non-operating volatility introduced by the company's digital asset treasury, thereby obscuring the underlying health of the core medical device business model.
Analysts should instead focus on normalized operating cash flow and revenue growth from the QuantaFlo platform to gauge the company's true operational health. Relying on P/E ratios in the current context may lead to a fundamental misunderstanding of the firm's risk profile and its transition away from a pure-play diagnostic provider.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SMLR stock.
Semler Scientific, Inc.'s current P/E ratio is 4.0x. The historical average is 31.5x.
Semler Scientific, Inc.'s current EV/EBITDA is 14.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 29.0x.
Semler Scientific, Inc.'s return on equity (ROE) is 27.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 12.3%.
Based on historical data, Semler Scientific, Inc. is trading at a P/E of 4.0x. Compare with industry peers and growth rates for a complete picture.
Semler Scientific, Inc. has 91.5% gross margin and 37.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Semler Scientific, Inc.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.